KOS 862
Alternative Names: Epothilone D; KOS-862; R 1492; Recombinant epothilone DLatest Information Update: 24 Oct 2021
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Epothilones; Small molecules
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Most Recent Events
- 27 Feb 2007 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
- 27 Feb 2007 Discontinued - Phase-II for Breast cancer in USA (IV-infusion)
- 05 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2006) have been added to the adverse events and therapeutic trials sections